Source - Alliance News

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Completes share buyback programme begun in July. Indivior buys back 9.4 million shares at average £8.25, worth £77.7 million, about $100.0 million, in total. The buyback was run by Morgan Stanley & Co International PLC. Last week, Indivior promoted David Wheadon to chair, starting immediately. Wheadon joined the Indivior board in June last year. Wheadon is a medical doctor who worked for GlaxoSmithKline, now GSK PLC, and Eli Lilly & Co. Until 2019, he was senior vice president of global regulatory affairs, patient safety & quality assurance at AstraZeneca PLC.

Current stock price: 930.00 pence each, down 1.3% on Tuesday morning in London

12-month change: down 32%

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Gsk PLC (GSK)

+10.11p (+0.72%)
delayed 10:52AM
JavaScript chart by amCharts 3.4.408:0009:3211:051,3951,4001,4051,4101,415Show all

Astrazeneca PLC (AZN)

+138.48p (+1.27%)
delayed 10:52AM
JavaScript chart by amCharts 3.4.408:0009:3011:0210,95011,00011,05011,10011,150Show all